Drug Trial Radar · NCT07219940
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Shine-On Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Conditions
- Healthy Subjects
- Exosome
- Targeted Therapy
Interventions
SOB100Drug
Drug: SOB100 Participants will receive SOB100 and evaluate the safety and tolerability of SOB100 during the dose escalation phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse event (AE)Time frame: From start until 3 weeks after the last dose of SOB100
- Incidence of serious adverse event (SAE)Time frame: From start until 3 weeks after the last dose of SOB100
- Incidence of treatment-emergent adverse event (TEAE)Time frame: From start until 3 weeks after the last dose of SOB100
- Abnormalities in physical examination (PE)Time frame: From start until 3 weeks after the last dose of SOB100
- Abnormalities in ECGTime frame: From start until 3 weeks after the last dose of SOB100
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International - Baltimore Early Phase Clinical Unit
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.